Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010

Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Immunomedics reports study results of antibody-SN-38 conjugates for targeted cancer chemotherapy

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Amgen announces results from pivotal Phase 3 "408" trial of Vectibix

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris commences perifosine Phase 3 registration trial

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

AVASTIN receives Health Canada approval for patients with GBM

AVASTIN receives Health Canada approval for patients with GBM

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics announces fourth-quarter and full-year 2009 financial results

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Erbitux improves survival of mCRC patients with KRAS wild-type tumors

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67